Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Dapagliflozin DPPIV Inhibitor add-on Study

ClinicalTrials.gov ID: NCT00984867

Public ClinicalTrials.gov record NCT00984867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study With 24 Week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.

Study identification

NCT ID
NCT00984867
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
833 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2009
Primary completion
Feb 28, 2011
Completion
Aug 31, 2011
Last update posted
Jun 12, 2014

2009 – 2011

United States locations

U.S. sites
45
U.S. states
21
U.S. cities
45
Facility City State ZIP Site status
Research Site Huntsville Alabama
Research Site Ozark Alabama
Research Site Anaheim California
Research Site Chula Vista California
Research Site Greenbrae California
Research Site Laguna Hills California
Research Site Los Angeles California
Research Site Riverside California
Research Site West Hills California
Research Site Boca Raton Florida
Research Site DeLand Florida
Research Site Jacksonville Florida
Research Site Longwood Florida
Research Site Miami Florida
Research Site Port Orange Florida
Research Site West Palm Beach Florida
Research Site Stone Mountain Georgia
Research Site Wichita Kansas
Research Site Lake Charles Louisiana
Research Site Edina Minnesota
Research Site St Louis Missouri
Research Site Las Vegas Nevada
Research Site Pahrump Nevada
Research Site Staten Island New York
Research Site Wilmington North Carolina
Research Site Cincinnati Ohio
Research Site Columbus Ohio
Research Site Dayton Ohio
Research Site Oklahoma City Oklahoma
Research Site Medord Oregon
Research Site Lancaster Pennsylvania
Research Site Philadelphia Pennsylvania
Research Site Mt. Pleasant South Carolina
Research Site Myrtle Beach South Carolina
Research Site Simpsonville South Carolina
Research Site Bristol Tennessee
Research Site Corpus Christi Texas
Research Site Dallas Texas
Research Site North Richland Hills Texas
Research Site San Antonio Texas
Research Site Salt Lake City Utah
Research Site Burke Virginia
Research Site Manassas Virginia
Research Site Richmond Virginia
Research Site Lakewood Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00984867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 12, 2014 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00984867 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →